Primary data · sourced from public filings·700+ listed companies · India-first·
Open screener
ἀλήθεια · aletheiaAncient Greek for truth — literally “un-forgetting”: the act of revealing reality, not merely stating it
← All posts
Sector Thesis·4 min read·Week 25

Why Pharma Tech Founders Over-Engineer First Products

Pharma tech founders in India build for the hospital they imagine, not the one buying. Over-engineering delays market entry by 18-24 months. The cost? Runway burns while competitors with 60% feature parity capture regulatory slots.

ByAmit Tyagi·Fitoor Capital
Aletheia Insights · Weekly

Get 1 unfair insight every week from India's startup ecosystem.

Read by serious founders and investors. No fluff.

Blog Pass

Continue reading with Blog Pass

This piece is part of the Aletheia archive. This week’s drops are free — unlock every sector thesis, deal-flow breakdown and disclosure note with a Blog Pass.

₹999/mo·₹5,000/yrSave 58%
Get Blog Pass →

Amit Tyagi

Founder, AletheiaAI & GP, Fitoor Capital

Veteran of India's startup ecosystem. Writing about fundraising, investor psychology, and what it takes to build fundable startups in India.

Run a fundability check

India's only MRE-backed platform for founders and investors. Analyse your deck, find investors, and validate your raise strategy.

#pharma-tech#product-strategy#india-startups#founder-lens

Don’t miss the next one

One insight every week. No fluff.

Aletheia Insights · Weekly

One contrarian insight. Every week. No generic startup advice.

Join founders and investors building with better information.

Why Pharma Tech Founders Over-Engineer First Products · Aletheia Insights